Dihexa Spray is Veracue’s spray-dispensed form of Dihexa, also catalogued under the developmental code PNB-0408, an angiotensin IV-derived oligopeptide built from N-hexanoyl-Tyr-Ile linked to a 6-aminohexanoic amide group. Its molecular formula is C27H44N4O5, average mass about 504.7 g/mol, CAS 1401708-83-5. In the lab it is studied in connection with the HGF/c-Met signaling pathway, a different target from the angiotensin receptors its parent peptide engages. Supplied as a 10 mg size for laboratory research use only.
Ask for the analytical documentation of any lot.
HPLC is the method used to measure purity
Ask for the report for a specific lot through the contact page
Supplied for laboratory research use only
Mass spectrometry is the method used to confirm identity
Dihexa Spray is Veracue's spray-dispensed packaging of Dihexa, a synthetic oligopeptide derived from angiotensin IV and also catalogued under the developmental code PNB-0408. The underlying molecule is identical to the one documented on Veracue's Dihexa vial listing; only the packaging and dispensing format differ between the two listings.
"Spray" is a packaging and dispensing descriptor, nothing more. It does not establish a route, a concentration, or a formulation, and none of those specifics should be inferred from the product name. Chemical form, concentration, fill volume and storage conditions are reported on each lot's own documentation and can be requested through the contact page.
| Product name | Dihexa Spray (also catalogued under the developmental code PNB-0408) |
| Packaging format | Spray-dispensed, Research Use Only |
| Compound class | Angiotensin IV-derived oligopeptide |
| Structure | N-hexanoyl-Tyr-Ile linked to a 6-aminohexanoic amide group |
| Research focus | HGF/c-Met pathway research |
| Molecular formula | C27H44N4O5 |
| Molecular weight | About 504.7 g/mol (sources report 504.66 to 504.672) |
| CAS Registry Number | 1401708-83-5 |
| Size offered | 10 mg |
| Research designation | Research Use Only |
Veracue lists Dihexa in more than one packaging format because research groups source and track material differently depending on how it is packaged. Keeping the formats as separate listings keeps lot records, images and documentation specific to the packaging a researcher actually ordered, rather than mixing records across formats.
Dihexa Spray and Veracue's Dihexa vial listing describe one molecule: N-hexanoyl-Tyr-Ile linked to a 6-aminohexanoic amide group, with the molecular formula C27H44N4O5, an average mass near 504.7 g/mol and CAS number 1401708-83-5. Packaging format has no bearing on structure, formula or mass, so these values are identical across both listings.
No. The compound reported under this listing is the same angiotensin IV-derived oligopeptide reported under the vial listing. What differs between the two listings is how the material is packaged and dispensed, not its chemical identity.
In Veracue's catalog, "Spray" is a packaging and dispensing term, comparable to "vial" or "powder" on other listings. It tells a researcher how the product is dispensed from its container. It does not specify a concentration, a carrier, a route, or a formulation, and it is not shorthand for any particular method of use. Those details, where applicable, live in lot-specific documentation rather than in the catalog name.
Treating a packaging word as a technical specification is a common source of error when comparing listings across suppliers. A researcher documenting materials in a methods section should cite the lot's own documentation for format-specific details rather than inferring them from the word "Spray" alone.
HGF and its receptor c-Met form a tyrosine kinase signaling pathway studied across several fields, including tissue biology and neurobiology. In the Dihexa literature, the reported mechanism is binding to HGF, which in turn potentiates HGF activity at c-Met. One cited binding value is a dissociation constant (Kd) near 65 picomolar. Packaging format has no bearing on this reported mechanism, since it describes the molecule itself.
Angiotensin IV has a long research history tied to a binding site once called the AT4 receptor, later linked by some researchers to insulin-regulated aminopeptidase (IRAP). A separate line of work proposed that several effects reported for angiotensin IV-derived peptides depend on the HGF/c-Met system instead. Dihexa was developed within that second line, as a stabilized analog for probing the pathway more directly, and that research lineage is the same whichever packaging format a lot is supplied in.
Angiotensin IV research spans decades and several receptor hypotheses. Findings about angiotensin IV itself should not be blended with findings about Dihexa. Check the methods section for the exact compound, by name or CAS number, before applying a result, regardless of which Veracue packaging format a lot was drawn from.
A finding that Dihexa potentiates HGF activity at c-Met explains how a compound might act in a given assay. It does not mean the same outcome appears in every system. Check the assay conditions, meaning the cell type, concentration range and readout, before assuming a result carries over to a different model.
Because "Spray" and "vial" describe packaging rather than chemistry, a methods section should still name the molecule precisely by structure or CAS number, and separately note the catalog format and lot number actually used. This page provides molecular reference information and general research context only, and Veracue provides no dosing guidance of any kind.
Identity and purity for Dihexa Spray are established the same way as for any Dihexa lot: reverse-phase HPLC for chromatographic purity, and mass spectrometry (typically ESI-MS or LC-MS) to confirm that the observed mass matches the molecule's theoretical value near 504.7 g/mol for C27H44N4O5. HPLC alone shows that most detected material elutes together; it does not by itself confirm identity, since a closely related compound can produce an equally clean trace.
Packaging format has no bearing on which analytical methods apply. A spray-dispensed lot and a vial lot of the same molecule are verified against the same structure, formula and mass references, listed on the Dihexa at a Glance table above.
| Method | Tells a researcher | Does not prove by itself |
|---|---|---|
| RP-HPLC | Chromatographic purity (area %) | Identity |
| ESI-MS / LC-MS | Mass consistent with C27H44N4O5 | Net peptide content; purity |
| Elemental analysis | Composition consistent with the reference formula | Identity of trace impurities |
| Reference comparison | Agreement with CAS 1401708-83-5 | Quantity or purity on its own |
A certificate of analysis describes one lot, never a packaging format or a compound in general. Before relying on any figure, confirm that the lot number on the certificate matches the container and the order record for the spray-format unit received.
A complete certificate separates product identity, lot number, chemical form, HPLC result with chromatogram, mass spectrometry result with observed and theoretical mass, test date and testing laboratory. Where concentration or fill-volume figures are relevant to a spray-format unit, they are reported on that lot's own documentation rather than inferred from the catalog listing. The certificate page explains how to request lot documentation for either format.
No. The verification question is the same: does this lot match the stated molecule, and is the purity figure paired with a mass result from the same lot. Packaging format does not change what counts as adequate documentation.
Dihexa is sold under more than one name across suppliers, including PNB-0408. If a lot's documentation leaves the stated identifier unclear, any mass-based comparison can carry a silent error. Confirm the name and CAS number on the lot's certificate and use the matching reference formula, regardless of packaging format.
For each lot, keep the catalog listing snapshot, the lot-specific certificate, the stated chemical form, the receipt date, labeled storage conditions, and the packaging format actually received. Recording format alongside the usual identity fields keeps multi-format catalogs like this one traceable lot to lot.
Dihexa Spray is supplied for laboratory research and analytical characterization only. It is not intended for human or veterinary use, or for ingestion, injection or any form of administration. This page contains no administration or usage guidance of any kind, and Veracue provides no dosing guidance for this or any research material. The word "Spray" in the product name describes Veracue's packaging and dispensing format only. See the Medical Disclaimer and the Terms and Conditions for sitewide policies.
RESEARCH PEPTIDE
Spray bottle pairing a 29-residue GHRH analog with the pentapeptide Ipamorelin, 5 mg of each and 45 sprays per bottle. Laboratory research use only.
RESEARCH PEPTIDE
GLP-T Spray pairs a 39-residue peptide, LY3298176 (CAS 2023788-19-2), with a C20 diacid on lysine 20. 10 to 60 mg, research use only, 45 sprays a bottle.
RESEARCH PEPTIDE
A 28-residue, N-acetylated peptide at 3108.3 g/mol, spray-dispensed in a 10 mg bottle with 45 sprays. Supplied for research use only.
RESEARCH PEPTIDE
Seven residues, a lactam ring and an amide terminus: Melanotan II, CAS 121062-08-6, in a 10 mg bottle of 45 sprays. Laboratory research only.
